Venous blood gases topic in detail
"venous blood gas" AND arterial correlation
"venous blood gas" AND "arterial blood gas" clinical utility
| Site | Source | Clinical Use |
|---|---|---|
| Peripheral vein | Arm/hand vein | Most common; easy access; widely used in ED |
| Central vein (SVC/right atrium) | Central venous catheter | Better for systemic assessment; ScvO2 monitoring |
| Pulmonary artery (mixed venous) | Pulmonary artery catheter (PAC) | Gold standard for true mixed venous; reflects global O2 balance |
| Parameter | Arterial (ABG) | Venous (VBG) | Difference |
|---|---|---|---|
| pH | 7.35 - 7.45 | ~7.32 - 7.42 | ~0.03-0.05 lower |
| PCO2 | 35 - 45 mmHg | ~40 - 50 mmHg | ~3-8 mmHg higher |
| PO2 | 80 - 100 mmHg | ~35 - 45 mmHg | Much lower (not usable for oxygenation) |
| HCO3- | 22 - 26 mEq/L | ~2-3 mEq/L higher | ~5% higher than arterial |
| O2 saturation (SvO2) | 95-100% | ~60-80% | Reflects tissue O2 extraction |
CO = VO2 / (CaO2 - CvO2)
| ScvO2 (SVC/right atrium) | SvO2 (pulmonary artery) | |
|---|---|---|
| Access | Central venous catheter | Pulmonary artery catheter |
| Represents | Upper body + cerebral | Entire body |
| Normal value | ~70-80% | ~65-75% |
| Reliability | Variable; not a reliable surrogate | Gold standard |
| Clinical Question | Use |
|---|---|
| Is oxygenation adequate? | ABG (or SpO2) - VBG cannot assess this |
| Is the patient hypercapnic? | VBG first; normal excludes hypercapnia. Confirm ABG if elevated or severe |
| What is the acid-base status? | VBG is acceptable (pH ±0.03-0.05) |
| Is bicarbonate normal? | VBG (HCO3- runs ~2-3 mEq/L higher than arterial) |
| Is lactate elevated? | VBG acceptable for screening; mildly elevated should be confirmed |
| Is global O2 delivery adequate? | Mixed SvO2 from PAC (or ScvO2 as trend) |
| Hypotensive / severely hypercapnic patient | ABG preferred; VBG unreliable |
PaCO2 = (1.5 × [HCO3-] + 8) ± 2
CO = VO2 / (CaO2 - CvO2)
VD/VT = (PaCO2 - PeCO2) / PaCO2
| Feature | VBG | ABG |
|---|---|---|
| Invasiveness | Low (venipuncture) | Higher (arterial puncture) |
| Pain | Minimal | Moderate |
| pH accuracy | Good (±0.03-0.05) | Reference standard |
| PCO2 | Elevated ~3-8 mmHg vs. arterial | Reference |
| PO2 / Oxygenation | Not useful | Required |
| HCO3- | ~2-3 mEq/L higher | Reference |
| Lactate | Acceptable (screen); confirm if mildly elevated | More accurate |
| Use in shock/hypotension | Unreliable | Preferred |
| SvO2 (mixed venous) | Via PAC only | N/A |
Can you make this into a pdf
ls -la /home/daytona/workspace/ 2>/dev/null || mkdir -p /home/daytona/workspace
mkdir -p /home/daytona/workspace/vbg-pdf && python3 -c "from reportlab.lib.pagesizes import A4; print('reportlab ok')" && python3 -c "from weasyprint import HTML; print('weasyprint ok')" 2>&1 || true
~/vbg-pdf/generate_vbg_pdf.py
from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.units import cm
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY
from reportlab.platypus import (
SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
HRFlowable, PageBreak
)
from reportlab.platypus.flowables import KeepTogether
OUTPUT = "/home/daytona/workspace/vbg-pdf/Venous_Blood_Gases.pdf"
doc = SimpleDocTemplate(
OUTPUT,
pagesize=A4,
leftMargin=2*cm, rightMargin=2*cm,
topMargin=2.2*cm, bottomMargin=2.2*cm,
title="Venous Blood Gases",
author="Orris Medical Reference"
)
W = A4[0] - 4*cm # usable width
# ── Colour palette ──────────────────────────────────────────────────────────
NAVY = colors.HexColor("#1a3a5c")
TEAL = colors.HexColor("#0d6e8a")
LIGHT = colors.HexColor("#e8f4f8")
ACCENT = colors.HexColor("#f0a500")
WHITE = colors.white
LGREY = colors.HexColor("#f5f5f5")
DGREY = colors.HexColor("#333333")
MGREY = colors.HexColor("#666666")
RED = colors.HexColor("#c0392b")
GREEN = colors.HexColor("#1a7a4a")
# ── Styles ───────────────────────────────────────────────────────────────────
styles = getSampleStyleSheet()
title_style = ParagraphStyle("Title", fontName="Helvetica-Bold",
fontSize=22, textColor=WHITE, alignment=TA_CENTER, leading=28)
subtitle_style = ParagraphStyle("Subtitle", fontName="Helvetica",
fontSize=11, textColor=colors.HexColor("#cce8f0"),
alignment=TA_CENTER, leading=16)
h1 = ParagraphStyle("H1", fontName="Helvetica-Bold",
fontSize=14, textColor=WHITE, leading=18,
backColor=NAVY, leftPadding=8, rightPadding=8,
spaceBefore=14, spaceAfter=4)
h2 = ParagraphStyle("H2", fontName="Helvetica-Bold",
fontSize=12, textColor=TEAL, leading=16,
spaceBefore=10, spaceAfter=3)
body = ParagraphStyle("Body", fontName="Helvetica",
fontSize=9.5, textColor=DGREY, leading=14,
spaceBefore=2, spaceAfter=2, alignment=TA_JUSTIFY)
bullet = ParagraphStyle("Bullet", fontName="Helvetica",
fontSize=9.5, textColor=DGREY, leading=14,
leftIndent=14, bulletIndent=4, spaceBefore=1, spaceAfter=1)
small_italic = ParagraphStyle("SmallItalic", fontName="Helvetica-Oblique",
fontSize=8.5, textColor=MGREY, leading=12,
spaceBefore=2, spaceAfter=4)
note_style = ParagraphStyle("Note", fontName="Helvetica",
fontSize=8.8, textColor=DGREY, leading=13,
backColor=LIGHT, leftPadding=8, rightPadding=8, borderPadding=6,
spaceBefore=4, spaceAfter=4)
warn_style = ParagraphStyle("Warn", fontName="Helvetica-Bold",
fontSize=9, textColor=RED, leading=13,
leftIndent=10, spaceBefore=2, spaceAfter=2)
source_style = ParagraphStyle("Source", fontName="Helvetica-Oblique",
fontSize=8, textColor=MGREY, leading=11,
spaceBefore=0, spaceAfter=0)
def h1_para(text):
return Paragraph(f" {text}", h1)
def h2_para(text):
return Paragraph(text, h2)
def para(text):
return Paragraph(text, body)
def bul(text):
return Paragraph(f"\u2022 {text}", bullet)
def src(text):
return Paragraph(f"<i>- {text}</i>", source_style)
# ── Helper: coloured table ───────────────────────────────────────────────────
def make_table(headers, rows, col_widths=None, header_bg=NAVY, alt=True):
data = [[Paragraph(f"<b>{h}</b>", ParagraphStyle("TH",
fontName="Helvetica-Bold", fontSize=9, textColor=WHITE,
leading=12, alignment=TA_CENTER))
for h in headers]]
for i, row in enumerate(rows):
data.append([Paragraph(str(cell), ParagraphStyle("TD",
fontName="Helvetica", fontSize=8.8,
textColor=DGREY, leading=12, alignment=TA_CENTER))
for cell in row])
style = [
("BACKGROUND", (0,0), (-1,0), header_bg),
("ROWBACKGROUNDS", (0,1), (-1,-1),
[LGREY, WHITE] if alt else [WHITE]),
("GRID", (0,0), (-1,-1), 0.4, colors.HexColor("#cccccc")),
("VALIGN", (0,0), (-1,-1), "MIDDLE"),
("TOPPADDING", (0,0), (-1,-1), 4),
("BOTTOMPADDING", (0,0), (-1,-1), 4),
("LEFTPADDING", (0,0), (-1,-1), 6),
("RIGHTPADDING", (0,0), (-1,-1), 6),
("LINEBELOW", (0,0), (-1,0), 1, ACCENT),
]
t = Table(data, colWidths=col_widths, repeatRows=1)
t.setStyle(TableStyle(style))
return t
# ── Build story ──────────────────────────────────────────────────────────────
story = []
# ── Cover banner ─────────────────────────────────────────────────────────────
banner_data = [[
Paragraph("Venous Blood Gases", title_style),
""
],[
Paragraph("A Comprehensive Clinical Reference", subtitle_style),
""
],[
Paragraph("Based on: Tintinalli's EM · Murray & Nadel's · Goldman-Cecil · Fishman's · Miller's Anesthesia · Rosen's EM", subtitle_style),
""
]]
banner = Table(banner_data, colWidths=[W, 0])
banner.setStyle(TableStyle([
("BACKGROUND", (0,0), (-1,-1), NAVY),
("TOPPADDING", (0,0), (-1,-1), 10),
("BOTTOMPADDING", (0,0), (-1,-1), 10),
("LEFTPADDING", (0,0), (-1,-1), 12),
("RIGHTPADDING", (0,0), (-1,-1), 12),
]))
story.append(banner)
story.append(Spacer(1, 0.5*cm))
# ── 1. Definition ─────────────────────────────────────────────────────────────
story.append(h1_para("1. What Is a Venous Blood Gas (VBG)?"))
story.append(Spacer(1, 0.15*cm))
story.append(para(
"A <b>venous blood gas (VBG)</b> is an analysis of blood taken from a venous source "
"to measure pH, PCO\u2082, PO\u2082, bicarbonate (HCO\u2083\u207b), and oxygen saturation. "
"It is less invasive and less painful than an arterial blood gas (ABG), making it widely "
"used in emergency medicine and critical care. Partially or centrally obtained venous "
"samples are both in routine clinical use."
))
story.append(src("Tintinalli's Emergency Medicine, p. 304 | Murray & Nadel's Textbook of Respiratory Medicine, p. 2280"))
story.append(Spacer(1, 0.2*cm))
# ── 2. Sampling Sites ────────────────────────────────────────────────────────
story.append(h1_para("2. Sampling Sites"))
story.append(Spacer(1, 0.15*cm))
story.append(make_table(
["Site", "Source", "Clinical Use"],
[
["Peripheral vein", "Arm / hand vein", "Most common; easy access; widely used in ED"],
["Central vein (SVC / right atrium)", "Central venous catheter",
"Better systemic assessment; ScvO\u2082 monitoring"],
["Pulmonary artery (mixed venous)", "Pulmonary artery catheter (PAC)",
"Gold standard for true mixed venous; reflects global O\u2082 balance"],
],
col_widths=[W*0.28, W*0.28, W*0.44]
))
story.append(Spacer(1, 0.2*cm))
story.append(bul(
"The <b>pulmonary artery</b> is the ideal site because blood from all body sites is equally "
"represented, but placement is rarely practical."
))
story.append(bul(
"Blood from the <b>SVC</b> disproportionately represents cerebral and upper body flow."
))
story.append(bul(
"<b>Peripheral venous</b> samples are widely used and correlate closely enough to be "
"clinically useful; significantly abnormal values should be confirmed with an ABG."
))
story.append(src("Tintinalli's Emergency Medicine, p. 304"))
story.append(Spacer(1, 0.2*cm))
# ── 3. Normal Values ─────────────────────────────────────────────────────────
story.append(h1_para("3. Normal VBG Values vs. ABG Values"))
story.append(Spacer(1, 0.15*cm))
story.append(make_table(
["Parameter", "Arterial (ABG)", "Venous (VBG)", "Typical Difference"],
[
["pH", "7.35 - 7.45", "~7.32 - 7.42", "~0.03 - 0.05 lower"],
["PCO\u2082 (mmHg)", "35 - 45", "~40 - 50", "~3 - 8 mmHg higher"],
["PO\u2082 (mmHg)", "80 - 100", "~35 - 45", "Much lower (not for oxygenation)"],
["HCO\u2083\u207b (mEq/L)", "22 - 26", "~24 - 29", "~2 - 3 mEq/L higher"],
["O\u2082 Saturation", "95 - 100%", "~60 - 80% (SvO\u2082)", "Reflects tissue O\u2082 extraction"],
],
col_widths=[W*0.22, W*0.22, W*0.22, W*0.34]
))
story.append(Spacer(1, 0.2*cm))
story.append(bul(
"Venous <b>HCO\u2083\u207b</b> runs ~2-3 mmol/L higher because venous blood includes CO\u2082 "
"from cellular metabolism not yet excreted by the lungs, plus carbonic acid, dissolved CO\u2082, "
"carbonate, and carbamates."
))
story.append(src("Murray & Nadel's, p. 2280-2282 | Goldman-Cecil Medicine, p. 754"))
story.append(Spacer(1, 0.2*cm))
# ── 4. What VBG Can and Cannot Tell You ──────────────────────────────────────
story.append(h1_para("4. What VBG Can and Cannot Tell You"))
story.append(Spacer(1, 0.15*cm))
story.append(h2_para("CAN Use VBG For:"))
story.append(bul(
"<b>pH assessment:</b> Correlates closely with arterial pH (±0.03-0.05 units). In most "
"clinical scenarios this difference is not clinically significant. Central VBGs are more "
"accurate than peripheral."
))
story.append(bul(
"<b>Hypercapnia screening:</b> A <b>normal PvCO\u2082 effectively excludes hypercapnic "
"respiratory failure.</b> If venous PCO\u2082 is normal, arterial PCO\u2082 is almost "
"certainly normal."
))
story.append(bul(
"<b>Acid-base disorders:</b> Excellent agreement with ABG for detecting acid-base disorders, "
"including in ICU patients in shock."
))
story.append(bul(
"<b>Bicarbonate estimation:</b> Venous total CO\u2082/HCO\u2083\u207b is a useful surrogate "
"for arterial HCO\u2083\u207b."
))
story.append(bul(
"<b>Lactate (screening):</b> Normal and markedly abnormal venous lactate correlates with "
"arterial lactate. Mildly elevated venous lactate may not reliably correlate - confirm with "
"arterial if clinically important."
))
story.append(bul(
"<b>DKA monitoring:</b> VBG correlates well with ABG for pH and HCO\u2083\u207b, avoiding "
"repeated arterial punctures."
))
story.append(Spacer(1, 0.15*cm))
story.append(h2_para("CANNOT Use VBG For:"))
story.append(Paragraph(
"\u26a0\ufe0f <b>Oxygenation assessment:</b> Venous PO\u2082 does NOT correlate with arterial "
"oxygen content and <b>cannot</b> be used to assess hypoxemia. ABG or SpO\u2082 is required.",
ParagraphStyle("WarnBox", fontName="Helvetica-Bold", fontSize=9.5,
textColor=RED, leading=14, leftIndent=14, spaceBefore=3, spaceAfter=3)
))
story.append(Paragraph(
"\u26a0\ufe0f <b>Reliable hypercarbia quantification when severe:</b> In low cardiac output, "
"high CO\u2082 production, or inhibition of red cell carbonic anhydrase, the arteriovenous "
"PCO\u2082 difference can increase up to <b>10-fold</b>, rendering VBG unreliable.",
ParagraphStyle("WarnBox2", fontName="Helvetica-Bold", fontSize=9.5,
textColor=RED, leading=14, leftIndent=14, spaceBefore=3, spaceAfter=3)
))
story.append(Paragraph(
"\u26a0\ufe0f <b>Hypotensive patients with severe hypercapnia:</b> VBGs are considered "
"unacceptably inaccurate. ABG is preferred.",
ParagraphStyle("WarnBox3", fontName="Helvetica-Bold", fontSize=9.5,
textColor=RED, leading=14, leftIndent=14, spaceBefore=3, spaceAfter=3)
))
story.append(src("Goldman-Cecil, p. 754 | Tintinalli's, p. 306 | Murray & Nadel's, p. 2280"))
story.append(Spacer(1, 0.2*cm))
# ── 5. Mixed Venous O2 Saturation ────────────────────────────────────────────
story.append(h1_para("5. Mixed Venous Oxygen Saturation (SvO\u2082)"))
story.append(Spacer(1, 0.15*cm))
story.append(para(
"The <b>mixed venous oxygen saturation (SvO\u2082)</b>, measured from the pulmonary artery "
"via a PAC, is a global indicator of the balance between oxygen delivery (DO\u2082) and "
"oxygen consumption (VO\u2082)."
))
story.append(Spacer(1, 0.1*cm))
story.append(make_table(
["SvO\u2082 Value", "Interpretation"],
[
["Normal: 65 - 75%", "Adequate global O\u2082 delivery/consumption balance"],
["Low: < 65%", "Global O\u2082 delivery deficient - low CO, severe anaemia, high metabolic state"],
["High: > 75 - 80%", "Distributive shock (e.g. sepsis), impaired tissue O\u2082 extraction, or high-flow state"],
],
col_widths=[W*0.30, W*0.70]
))
story.append(Spacer(1, 0.15*cm))
story.append(para(
"<b>Fick's principle</b> allows cardiac output estimation using SvO\u2082:"
))
# Formula box
formula_table = Table(
[[Paragraph("CO = VO\u2082 / (CaO\u2082 \u2212 CvO\u2082)",
ParagraphStyle("Formula", fontName="Helvetica-Bold", fontSize=11,
textColor=NAVY, leading=16, alignment=TA_CENTER))]],
colWidths=[W]
)
formula_table.setStyle(TableStyle([
("BACKGROUND", (0,0), (-1,-1), LIGHT),
("BOX", (0,0), (-1,-1), 1, TEAL),
("TOPPADDING", (0,0), (-1,-1), 8),
("BOTTOMPADDING", (0,0), (-1,-1), 8),
]))
story.append(formula_table)
story.append(Spacer(1, 0.1*cm))
story.append(bul(
"<b>Important limitation:</b> SvO\u2082 is a <i>global</i> measure. Organ-specific ischemia "
"may be present even with a normal or elevated mixed venous saturation."
))
story.append(src("Miller's Anesthesia 10e, p. 833-835"))
story.append(Spacer(1, 0.2*cm))
# ScvO2 vs SvO2
story.append(h2_para("Central Venous O\u2082 Saturation (ScvO\u2082) vs. Mixed Venous (SvO\u2082)"))
story.append(make_table(
["", "ScvO\u2082 (SVC / right atrium)", "SvO\u2082 (pulmonary artery)"],
[
["Access", "Central venous catheter", "Pulmonary artery catheter (PAC)"],
["Represents", "Upper body + cerebral flow", "Entire body"],
["Normal value", "~70 - 80%", "~65 - 75%"],
["Reliability", "Variable; NOT a reliable SvO\u2082 surrogate", "Gold standard"],
],
col_widths=[W*0.22, W*0.39, W*0.39]
))
story.append(Spacer(1, 0.1*cm))
story.append(bul(
"Monitoring of ScvO\u2082 was previously part of the <b>Surviving Sepsis Campaign</b>, but "
"failure to demonstrate clinical benefit led to its <b>removal from the 2016 guidelines</b>."
))
story.append(src("Tintinalli's, p. 308 | Miller's Anesthesia, p. 835"))
story.append(Spacer(1, 0.2*cm))
# ── 6. A-V Differences ───────────────────────────────────────────────────────
story.append(h1_para("6. Arteriovenous Differences - Why They Exist"))
story.append(Spacer(1, 0.15*cm))
story.append(para(
"Venous blood is lower in O\u2082 and higher in CO\u2082 because tissues extract oxygen and "
"produce CO\u2082. Normal arteriovenous differences:"
))
story.append(Spacer(1, 0.1*cm))
story.append(make_table(
["Parameter", "Arterial", "Venous", "Normal A-V Difference"],
[
["pH", "7.35 - 7.45", "~0.03 - 0.05 lower", "Vein is more acidic"],
["PCO\u2082 (mmHg)", "35 - 45", "~40 - 50", "3 - 8 mmHg higher venously"],
["PO\u2082 (mmHg)", "80 - 100", "~35 - 45", "~50 - 60 mmHg lower venously"],
["HCO\u2083\u207b (mEq/L)", "22 - 26", "~24 - 29", "~2 - 3 mEq/L higher venously"],
],
col_widths=[W*0.22, W*0.22, W*0.22, W*0.34]
))
story.append(Spacer(1, 0.1*cm))
story.append(bul(
"These differences <b>widen significantly in low-flow states</b> (shock, heart failure) "
"because tissues extract proportionally more O\u2082 and dump more CO\u2082."
))
story.append(Spacer(1, 0.2*cm))
# ── 7. Pre-Analytical Errors ─────────────────────────────────────────────────
story.append(h1_para("7. Pre-Analytical Errors Affecting VBG Accuracy"))
story.append(Spacer(1, 0.15*cm))
story.append(make_table(
["Error", "Effect on Values"],
[
["Air exposure", "Decreases PCO\u2082, raises pH, gradually decreases CO\u2082 content"],
["Saline / fluid dilution (from flush line)", "PCO\u2082 and HCO\u2083\u207b both fall equally"],
["Hypothermia (no temperature correction)", "Spuriously higher PCO\u2082, lower pH, higher PO\u2082"],
["Hyperthermia (no temperature correction)", "Opposite of hypothermia effects"],
["Delayed analysis (prolonged sample time)", "Continued cellular metabolism alters values"],
],
col_widths=[W*0.45, W*0.55]
))
story.append(src("Murray & Nadel's, p. 2274-2278"))
story.append(Spacer(1, 0.2*cm))
# ── 8. Clinical Applications ─────────────────────────────────────────────────
story.append(h1_para("8. Clinical Applications"))
story.append(Spacer(1, 0.15*cm))
story.append(h2_para("Emergency Medicine"))
for pt in [
"<b>Respiratory failure screening:</b> A normal venous PCO\u2082 excludes hypercapnic failure. Severe hypercapnia or hypoxia - confirm with ABG.",
"<b>DKA monitoring:</b> VBG correlates well with ABG for pH/HCO\u2083\u207b, avoiding repeated arterial punctures.",
"<b>Toxicology:</b> VBG used alongside electrolytes in phenol exposure, toxic ingestions.",
"<b>Paediatric assessment:</b> VBG used with glucose, ammonia, and metabolic panel in metabolic emergencies.",
]:
story.append(bul(pt))
story.append(Spacer(1, 0.1*cm))
story.append(h2_para("Critical Care / ICU"))
for pt in [
"<b>Acid-base monitoring:</b> Central VBGs have excellent agreement with ABGs for acid-base assessment, including in patients in shock.",
"<b>Sepsis:</b> ScvO\u2082 monitoring (no longer a Surviving Sepsis Campaign recommendation as of 2016).",
"<b>Haemorrhagic shock:</b> VBG alongside TEG and type-and-screen is prioritised in severe haemorrhagic shock.",
"<b>COPD exacerbation:</b> VBG recommended as initial blood gas; follow with ABG if severe hypercapnia or hypoxia.",
]:
story.append(bul(pt))
story.append(Spacer(1, 0.1*cm))
story.append(h2_para("Surgery / Anaesthesia"))
story.append(bul(
"Continuous SvO\u2082 monitoring via PAC in high-risk surgical patients provides real-time "
"assessment of global perfusion adequacy."
))
story.append(src("Tintinalli's, p. 304-310 | Rosen's EM, p. 2550 | Fishman's Pulmonary Diseases, p. 2060-2061"))
story.append(Spacer(1, 0.2*cm))
# ── 9. VBG vs ABG Decision Table ─────────────────────────────────────────────
story.append(h1_para("9. VBG vs. ABG - When to Choose Which"))
story.append(Spacer(1, 0.15*cm))
story.append(make_table(
["Clinical Question", "Recommended Test"],
[
["Is oxygenation adequate?", "ABG or SpO\u2082 - VBG cannot assess this"],
["Is the patient hypercapnic?", "VBG first; normal excludes hypercapnia. Confirm ABG if elevated"],
["What is the acid-base status?", "VBG is acceptable (pH \u00b10.03-0.05)"],
["Is bicarbonate normal?", "VBG (HCO\u2083\u207b ~2-3 mEq/L higher than arterial)"],
["Is lactate elevated?", "VBG for screening; mildly elevated should be confirmed with ABG"],
["Is global O\u2082 delivery adequate?", "Mixed SvO\u2082 from PAC (or ScvO\u2082 as a trend)"],
["Hypotensive / severely hypercapnic patient", "ABG preferred; VBG unreliable in this setting"],
],
col_widths=[W*0.50, W*0.50]
))
story.append(Spacer(1, 0.2*cm))
# ── 10. Key Formulas ─────────────────────────────────────────────────────────
story.append(h1_para("10. Key Formulas"))
story.append(Spacer(1, 0.15*cm))
formulas = [
("Winter's Equation", "Expected PaCO\u2082 in metabolic acidosis",
"PaCO\u2082 = (1.5 \u00d7 [HCO\u2083\u207b] + 8) \u00b1 2",
"PaCO\u2082 above expected = inadequate ventilatory response"),
("Fick Equation", "Cardiac output from mixed venous saturation",
"CO = VO\u2082 / (CaO\u2082 \u2212 CvO\u2082)",
"Requires SvO\u2082 from pulmonary artery"),
("Dead Space Fraction", "Requires ABG; gauges severity of lung disease",
"V\u1d05/V\u1d1b = (PaCO\u2082 \u2212 PeCO\u2082) / PaCO\u2082",
"PeCO\u2082 measured by metabolic monitor or capnography"),
]
for name, desc, formula, note in formulas:
row_data = [[
Paragraph(f"<b>{name}</b>",
ParagraphStyle("FN", fontName="Helvetica-Bold", fontSize=9.5,
textColor=NAVY, leading=13)),
Paragraph(desc,
ParagraphStyle("FD", fontName="Helvetica", fontSize=9,
textColor=MGREY, leading=13)),
Paragraph(formula,
ParagraphStyle("FF", fontName="Helvetica-Bold", fontSize=10,
textColor=TEAL, leading=14, alignment=TA_CENTER)),
Paragraph(f"<i>{note}</i>",
ParagraphStyle("FNote", fontName="Helvetica-Oblique", fontSize=8.5,
textColor=MGREY, leading=12)),
]]
t = Table(row_data, colWidths=[W*0.22, W*0.26, W*0.28, W*0.24])
t.setStyle(TableStyle([
("BACKGROUND", (0,0), (-1,-1), LGREY),
("BOX", (0,0), (-1,-1), 0.5, colors.HexColor("#cccccc")),
("LINEAFTER", (0,0), (2,0), 0.5, colors.HexColor("#cccccc")),
("VALIGN", (0,0), (-1,-1), "MIDDLE"),
("TOPPADDING", (0,0), (-1,-1), 6),
("BOTTOMPADDING", (0,0), (-1,-1), 6),
("LEFTPADDING", (0,0), (-1,-1), 8),
("RIGHTPADDING", (0,0), (-1,-1), 8),
]))
story.append(t)
story.append(Spacer(1, 0.1*cm))
story.append(Spacer(1, 0.2*cm))
# ── 11. Summary Table ────────────────────────────────────────────────────────
story.append(h1_para("11. Summary Comparison Table"))
story.append(Spacer(1, 0.15*cm))
story.append(make_table(
["Feature", "VBG", "ABG"],
[
["Invasiveness", "Low (venipuncture)", "Higher (arterial puncture)"],
["Pain", "Minimal", "Moderate"],
["pH accuracy", "Good (\u00b10.03-0.05)", "Reference standard"],
["PCO\u2082", "~3-8 mmHg higher than arterial", "Reference"],
["PO\u2082 / Oxygenation", "\u274c Not useful", "\u2705 Required for O\u2082 assessment"],
["HCO\u2083\u207b", "~2-3 mEq/L higher", "Reference"],
["Lactate", "Acceptable (screen); confirm if mildly elevated", "More accurate"],
["Use in shock / hypotension", "\u26a0 Unreliable", "\u2705 Preferred"],
["Mixed venous O\u2082 (SvO\u2082)", "Via PAC only", "N/A"],
],
col_widths=[W*0.32, W*0.35, W*0.33]
))
story.append(Spacer(1, 0.3*cm))
# ── References ────────────────────────────────────────────────────────────────
story.append(HRFlowable(width=W, thickness=1, color=TEAL))
story.append(Spacer(1, 0.1*cm))
story.append(Paragraph("<b>References</b>", ParagraphStyle("RefHead",
fontName="Helvetica-Bold", fontSize=10, textColor=NAVY, leading=14)))
story.append(Spacer(1, 0.05*cm))
refs = [
"Tintinalli's Emergency Medicine: A Comprehensive Study Guide, pp. 304-310",
"Murray & Nadel's Textbook of Respiratory Medicine, pp. 2270-2282",
"Goldman-Cecil Medicine International Edition, p. 754",
"Fishman's Pulmonary Diseases and Disorders, p. 2060",
"Miller's Anesthesia 10th Edition, pp. 833-835",
"Rosen's Emergency Medicine: Concepts and Clinical Practice, pp. 2550-2551",
"Harrison's Principles of Internal Medicine 22E (2025)",
]
for r in refs:
story.append(Paragraph(f"\u2022 {r}", ParagraphStyle("Ref",
fontName="Helvetica", fontSize=8.5, textColor=MGREY,
leading=12, leftIndent=12, spaceBefore=1)))
# ── Page numbers via canvas ──────────────────────────────────────────────────
def add_page_number(canvas, doc):
canvas.saveState()
canvas.setFont("Helvetica", 8)
canvas.setFillColor(MGREY)
canvas.drawRightString(A4[0] - 2*cm, 1.2*cm, f"Page {doc.page}")
canvas.drawString(2*cm, 1.2*cm, "Venous Blood Gases - Orris Medical Reference")
canvas.restoreState()
doc.build(story, onFirstPage=add_page_number, onLaterPages=add_page_number)
print(f"PDF created: {OUTPUT}")
cd /home/daytona/workspace/vbg-pdf && python3 generate_vbg_pdf.py 2>&1
ls -lh /home/daytona/workspace/vbg-pdf/Venous_Blood_Gases.pdf
Venous Blood Gases
PDF Document · PDF
The pdf does not work
pandoc --version 2>&1 | head -3; wkhtmltopdf --version 2>&1 | head -3; which libreoffice 2>&1
~/vbg-pdf/vbg.html
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Venous Blood Gases – Clinical Reference</title>
<style>
@page { size: A4; margin: 2cm 2.2cm 2cm 2.2cm; }
* { box-sizing: border-box; margin: 0; padding: 0; }
body { font-family: Arial, Helvetica, sans-serif; font-size: 10pt; color: #222; line-height: 1.5; }
/* HEADER BANNER */
.banner { background: #1a3a5c; color: white; padding: 18px 22px 14px; margin-bottom: 18px; }
.banner h1 { font-size: 22pt; font-weight: bold; margin-bottom: 4px; }
.banner .sub { font-size: 10pt; color: #cce8f0; }
/* SECTION HEADINGS */
h2 { background: #1a3a5c; color: white; font-size: 12pt; padding: 5px 10px;
margin: 18px 0 6px; }
h3 { color: #0d6e8a; font-size: 11pt; margin: 10px 0 4px; border-bottom: 1px solid #c0dde8; padding-bottom: 2px; }
p { margin-bottom: 6px; text-align: justify; }
ul { margin: 4px 0 6px 20px; }
ul li { margin-bottom: 3px; }
/* TABLES */
table { border-collapse: collapse; width: 100%; margin: 8px 0 10px; font-size: 9pt; }
thead tr { background: #1a3a5c; color: white; }
thead th { padding: 6px 8px; text-align: center; border-bottom: 2px solid #f0a500; }
tbody tr:nth-child(even) { background: #f5f5f5; }
tbody tr:nth-child(odd) { background: #ffffff; }
tbody td { padding: 5px 8px; border: 1px solid #ddd; vertical-align: top; }
/* FORMULA BOX */
.formula { background: #e8f4f8; border: 1.5px solid #0d6e8a; border-radius: 4px;
text-align: center; padding: 10px; margin: 8px 0; font-size: 12pt;
font-weight: bold; color: #1a3a5c; }
/* WARNING BOXES */
.warn { color: #c0392b; font-weight: bold; padding: 2px 0 2px 12px;
border-left: 3px solid #c0392b; margin: 4px 0; }
/* NOTE BOX */
.note { background: #e8f4f8; padding: 8px 12px; margin: 6px 0; font-size: 9pt; }
/* SOURCE CITATIONS */
.src { font-style: italic; color: #777; font-size: 8pt; margin-top: 2px; margin-bottom: 6px; }
/* REFERENCES */
.refs { border-top: 1px solid #0d6e8a; margin-top: 16px; padding-top: 8px; }
.refs h3 { color: #1a3a5c; border-bottom: none; }
.refs li { font-size: 8.5pt; color: #555; }
/* FOOTER NOTE */
.footer { font-size: 8pt; color: #aaa; text-align: center; margin-top: 20px; border-top: 1px solid #eee; padding-top: 6px; }
</style>
</head>
<body>
<!-- BANNER -->
<div class="banner">
<h1>Venous Blood Gases (VBG)</h1>
<div class="sub">A Comprehensive Clinical Reference</div>
<div class="sub" style="margin-top:4px; font-size:9pt;">
Based on: Tintinalli's EM · Murray & Nadel's · Goldman-Cecil · Fishman's · Miller's Anesthesia · Rosen's EM
</div>
</div>
<!-- 1. DEFINITION -->
<h2>1. What Is a Venous Blood Gas (VBG)?</h2>
<p>
A <strong>venous blood gas (VBG)</strong> is an analysis of blood taken from a venous source to measure
pH, PCO<sub>2</sub>, PO<sub>2</sub>, bicarbonate (HCO<sub>3</sub><sup>−</sup>), and oxygen saturation.
It is less invasive and less painful than an arterial blood gas (ABG), making it widely used in
emergency medicine and critical care. Both peripherally and centrally obtained venous samples are in
routine clinical use.
</p>
<p class="src">— Tintinalli's Emergency Medicine, p. 304 | Murray & Nadel's Textbook of Respiratory Medicine, p. 2280</p>
<!-- 2. SAMPLING SITES -->
<h2>2. Sampling Sites</h2>
<table>
<thead><tr><th>Site</th><th>Source</th><th>Clinical Use</th></tr></thead>
<tbody>
<tr>
<td><strong>Peripheral vein</strong></td>
<td>Arm / hand vein</td>
<td>Most common; easy access; widely used in ED</td>
</tr>
<tr>
<td><strong>Central vein (SVC / right atrium)</strong></td>
<td>Central venous catheter</td>
<td>Better systemic assessment; ScvO<sub>2</sub> monitoring</td>
</tr>
<tr>
<td><strong>Pulmonary artery (mixed venous)</strong></td>
<td>Pulmonary artery catheter (PAC)</td>
<td>Gold standard for true mixed venous; reflects global O<sub>2</sub> balance</td>
</tr>
</tbody>
</table>
<ul>
<li>The <strong>pulmonary artery</strong> is the ideal site because blood from all body sites is equally represented, but it is rarely practical to obtain.</li>
<li>Blood from the <strong>SVC</strong> disproportionately represents cerebral and upper body blood flow.</li>
<li><strong>Peripheral venous</strong> samples correlate closely enough to be clinically useful; significantly abnormal values should be confirmed with an ABG.</li>
</ul>
<p class="src">— Tintinalli's Emergency Medicine, p. 304</p>
<!-- 3. NORMAL VALUES -->
<h2>3. Normal VBG Values vs. ABG Values</h2>
<table>
<thead><tr><th>Parameter</th><th>Arterial (ABG)</th><th>Venous (VBG)</th><th>Typical Difference</th></tr></thead>
<tbody>
<tr><td><strong>pH</strong></td><td>7.35 – 7.45</td><td>~7.32 – 7.42</td><td>~0.03 – 0.05 lower</td></tr>
<tr><td><strong>PCO<sub>2</sub> (mmHg)</strong></td><td>35 – 45</td><td>~40 – 50</td><td>~3 – 8 mmHg higher</td></tr>
<tr><td><strong>PO<sub>2</sub> (mmHg)</strong></td><td>80 – 100</td><td>~35 – 45</td><td>Much lower (not usable for oxygenation)</td></tr>
<tr><td><strong>HCO<sub>3</sub><sup>−</sup> (mEq/L)</strong></td><td>22 – 26</td><td>~24 – 29</td><td>~2 – 3 mEq/L higher</td></tr>
<tr><td><strong>O<sub>2</sub> Saturation</strong></td><td>95 – 100%</td><td>~60 – 80% (SvO<sub>2</sub>)</td><td>Reflects tissue O<sub>2</sub> extraction</td></tr>
</tbody>
</table>
<ul>
<li>Venous <strong>HCO<sub>3</sub><sup>−</sup></strong> runs ~2–3 mmol/L higher because venous blood includes CO<sub>2</sub> from cellular metabolism not yet excreted by the lungs, plus carbonic acid, dissolved CO<sub>2</sub>, carbonate, and carbamates.</li>
<li>Venous pH averages ~0.03 lower than arterial (central VBG); peripheral VBG may differ by up to ±0.05.</li>
</ul>
<p class="src">— Murray & Nadel's, p. 2280–2282 | Goldman-Cecil Medicine, p. 754</p>
<!-- 4. CAN / CANNOT -->
<h2>4. What VBG Can and Cannot Tell You</h2>
<h3>✓ CAN Use VBG For:</h3>
<ul>
<li><strong>pH assessment:</strong> Correlates closely with arterial pH (±0.03–0.05 units). In most clinical scenarios this difference is not clinically significant. Central VBGs are more accurate than peripheral.</li>
<li><strong>Hypercapnia screening:</strong> A <strong>normal PvCO<sub>2</sub> effectively excludes hypercapnic respiratory failure.</strong> If venous PCO<sub>2</sub> is normal, arterial PCO<sub>2</sub> is almost certainly normal.</li>
<li><strong>Acid-base disorders:</strong> Excellent agreement with ABG for detecting acid-base disorders, including in ICU patients in shock.</li>
<li><strong>Bicarbonate estimation:</strong> Venous total CO<sub>2</sub>/HCO<sub>3</sub><sup>−</sup> is a useful surrogate for arterial HCO<sub>3</sub><sup>−</sup>.</li>
<li><strong>Lactate (screening):</strong> Normal and markedly abnormal venous lactate correlates with arterial lactate. Mildly elevated venous lactate may not reliably correlate — confirm with arterial if clinically important.</li>
<li><strong>DKA monitoring:</strong> VBG correlates well with ABG for pH and HCO<sub>3</sub><sup>−</sup>, avoiding repeated arterial punctures.</li>
</ul>
<h3>✗ CANNOT Use VBG For:</h3>
<div class="warn">⚠ Oxygenation assessment: Venous PO<sub>2</sub> does NOT correlate with arterial oxygen content and <u>cannot</u> be used to assess hypoxaemia. ABG or SpO<sub>2</sub> is required.</div>
<div class="warn">⚠ Reliable hypercarbia quantification when severe: In low cardiac output, high CO<sub>2</sub> production, or inhibition of red cell carbonic anhydrase, the arteriovenous PCO<sub>2</sub> difference can increase up to <strong>10-fold</strong>, rendering VBG unreliable.</div>
<div class="warn">⚠ Hypotensive patients with severe hypercapnia: VBGs are considered unacceptably inaccurate. ABG is preferred.</div>
<p class="src">— Goldman-Cecil, p. 754 | Tintinalli's, p. 306 | Murray & Nadel's, p. 2280</p>
<!-- 5. MIXED VENOUS -->
<h2>5. Mixed Venous Oxygen Saturation (SvO<sub>2</sub>)</h2>
<p>
The <strong>mixed venous oxygen saturation (SvO<sub>2</sub>)</strong>, measured from the pulmonary artery
via a PAC, is a global indicator of the balance between oxygen delivery (DO<sub>2</sub>) and oxygen
consumption (VO<sub>2</sub>).
</p>
<table>
<thead><tr><th>SvO<sub>2</sub> Value</th><th>Interpretation</th></tr></thead>
<tbody>
<tr><td>Normal: 65 – 75%</td><td>Adequate global O<sub>2</sub> delivery/consumption balance</td></tr>
<tr><td>Low: < 65%</td><td>Global O<sub>2</sub> delivery deficient — low cardiac output, severe anaemia, high metabolic demand</td></tr>
<tr><td>High: > 75 – 80%</td><td>Distributive shock (e.g. sepsis), impaired tissue O<sub>2</sub> extraction, or high-flow states</td></tr>
</tbody>
</table>
<p><strong>Fick's Principle</strong> — cardiac output estimation using SvO<sub>2</sub>:</p>
<div class="formula">CO = VO<sub>2</sub> / (CaO<sub>2</sub> − CvO<sub>2</sub>)</div>
<ul>
<li><strong>Important limitation:</strong> SvO<sub>2</sub> is a <em>global</em> measure. Organ-specific ischaemia may be present even with a normal or elevated mixed venous saturation.</li>
</ul>
<p class="src">— Miller's Anesthesia 10e, p. 833–835</p>
<h3>Central Venous O<sub>2</sub> Saturation (ScvO<sub>2</sub>) vs. Mixed Venous (SvO<sub>2</sub>)</h3>
<table>
<thead><tr><th></th><th>ScvO<sub>2</sub> (SVC / right atrium)</th><th>SvO<sub>2</sub> (pulmonary artery)</th></tr></thead>
<tbody>
<tr><td><strong>Access</strong></td><td>Central venous catheter</td><td>Pulmonary artery catheter (PAC)</td></tr>
<tr><td><strong>Represents</strong></td><td>Upper body + cerebral flow</td><td>Entire body</td></tr>
<tr><td><strong>Normal value</strong></td><td>~70 – 80%</td><td>~65 – 75%</td></tr>
<tr><td><strong>Reliability</strong></td><td>Variable; NOT a reliable SvO<sub>2</sub> surrogate</td><td>Gold standard</td></tr>
</tbody>
</table>
<ul>
<li>Monitoring of ScvO<sub>2</sub> was previously part of the <strong>Surviving Sepsis Campaign</strong>, but failure to demonstrate clinical benefit led to its <strong>removal from the 2016 guidelines</strong>.</li>
</ul>
<p class="src">— Tintinalli's, p. 308 | Miller's Anesthesia, p. 835</p>
<!-- 6. A-V DIFFERENCES -->
<h2>6. Arteriovenous Differences — Why They Exist</h2>
<p>
Venous blood is lower in O<sub>2</sub> and higher in CO<sub>2</sub> because tissues extract oxygen
and produce CO<sub>2</sub>. These differences widen significantly in low-flow states (shock, heart failure).
</p>
<table>
<thead><tr><th>Parameter</th><th>Arterial</th><th>Venous</th><th>Normal A-V Difference</th></tr></thead>
<tbody>
<tr><td>pH</td><td>7.35 – 7.45</td><td>~0.03–0.05 lower</td><td>Vein is more acidic</td></tr>
<tr><td>PCO<sub>2</sub> (mmHg)</td><td>35 – 45</td><td>~40 – 50</td><td>3 – 8 mmHg higher venously</td></tr>
<tr><td>PO<sub>2</sub> (mmHg)</td><td>80 – 100</td><td>~35 – 45</td><td>~50 – 60 mmHg lower venously</td></tr>
<tr><td>HCO<sub>3</sub><sup>−</sup> (mEq/L)</td><td>22 – 26</td><td>~24 – 29</td><td>~2 – 3 mEq/L higher venously</td></tr>
</tbody>
</table>
<!-- 7. PRE-ANALYTICAL ERRORS -->
<h2>7. Pre-Analytical Errors Affecting VBG Accuracy</h2>
<table>
<thead><tr><th>Error</th><th>Effect on Values</th></tr></thead>
<tbody>
<tr><td><strong>Air exposure</strong></td><td>Decreases PCO<sub>2</sub>, raises pH, gradually decreases CO<sub>2</sub> content</td></tr>
<tr><td><strong>Saline/fluid dilution</strong> (e.g. flush line)</td><td>PCO<sub>2</sub> and HCO<sub>3</sub><sup>−</sup> both fall equally</td></tr>
<tr><td><strong>Hypothermia</strong> (no temperature correction)</td><td>Spuriously higher PCO<sub>2</sub>, lower pH, higher PO<sub>2</sub></td></tr>
<tr><td><strong>Hyperthermia</strong> (no temperature correction)</td><td>Opposite of hypothermia effects</td></tr>
<tr><td><strong>Delayed analysis</strong></td><td>Continued cellular metabolism alters all values</td></tr>
</tbody>
</table>
<p class="src">— Murray & Nadel's, p. 2274–2278</p>
<!-- 8. CLINICAL APPLICATIONS -->
<h2>8. Clinical Applications</h2>
<h3>Emergency Medicine</h3>
<ul>
<li><strong>Respiratory failure screening:</strong> A normal venous PCO<sub>2</sub> excludes hypercapnic failure. If severe hypercapnia or hypoxia, confirm with ABG.</li>
<li><strong>DKA monitoring:</strong> VBG correlates well with ABG for pH/HCO<sub>3</sub><sup>−</sup>, avoiding repeated arterial punctures.</li>
<li><strong>Toxicology:</strong> VBG used alongside electrolytes in phenol exposure and toxic ingestions.</li>
<li><strong>Paediatric assessment:</strong> VBG used with glucose, ammonia, and metabolic panel in metabolic emergencies.</li>
</ul>
<h3>Critical Care / ICU</h3>
<ul>
<li><strong>Acid-base monitoring:</strong> Central VBGs have excellent agreement with ABGs for acid-base assessment, including in patients in shock.</li>
<li><strong>Sepsis:</strong> ScvO<sub>2</sub> monitoring (no longer a Surviving Sepsis Campaign recommendation as of 2016).</li>
<li><strong>Haemorrhagic shock:</strong> VBG alongside TEG and type-and-screen prioritised in severe haemorrhagic shock.</li>
<li><strong>COPD exacerbation:</strong> VBG recommended as initial blood gas; follow with ABG if severe hypercapnia or hypoxia.</li>
</ul>
<h3>Surgery / Anaesthesia</h3>
<ul>
<li>Continuous SvO<sub>2</sub> monitoring via PAC in high-risk surgical patients provides real-time assessment of global perfusion adequacy.</li>
</ul>
<p class="src">— Tintinalli's, p. 304–310 | Rosen's EM, p. 2550 | Fishman's Pulmonary Diseases, p. 2060–2061</p>
<!-- 9. DECISION TABLE -->
<h2>9. VBG vs. ABG — When to Choose Which</h2>
<table>
<thead><tr><th>Clinical Question</th><th>Recommended Test</th></tr></thead>
<tbody>
<tr><td>Is oxygenation adequate?</td><td>ABG or SpO<sub>2</sub> — VBG cannot assess this</td></tr>
<tr><td>Is the patient hypercapnic?</td><td>VBG first; normal excludes hypercapnia. Confirm ABG if elevated or severe</td></tr>
<tr><td>What is the acid-base status?</td><td>VBG is acceptable (pH ±0.03–0.05)</td></tr>
<tr><td>Is bicarbonate normal?</td><td>VBG (HCO<sub>3</sub><sup>−</sup> ~2–3 mEq/L higher than arterial)</td></tr>
<tr><td>Is lactate elevated?</td><td>VBG for screening; mildly elevated should be confirmed with ABG</td></tr>
<tr><td>Is global O<sub>2</sub> delivery adequate?</td><td>Mixed SvO<sub>2</sub> from PAC (or ScvO<sub>2</sub> as a trend)</td></tr>
<tr><td>Hypotensive / severely hypercapnic patient</td><td>ABG preferred; VBG unreliable in this setting</td></tr>
</tbody>
</table>
<!-- 10. FORMULAS -->
<h2>10. Key Formulas</h2>
<h3>Winter's Equation — Expected PaCO<sub>2</sub> in metabolic acidosis</h3>
<div class="formula">PaCO<sub>2</sub> = (1.5 × [HCO<sub>3</sub><sup>−</sup>] + 8) ± 2</div>
<p>A measured PaCO<sub>2</sub> <em>above</em> the expected value indicates an inadequate ventilatory response to the metabolic acidosis.</p>
<h3>Fick Equation — Cardiac output from mixed venous saturation</h3>
<div class="formula">CO = VO<sub>2</sub> / (CaO<sub>2</sub> − CvO<sub>2</sub>)</div>
<p>Requires SvO<sub>2</sub> measured at the pulmonary artery.</p>
<h3>Dead Space Fraction — Requires ABG</h3>
<div class="formula">V<sub>D</sub>/V<sub>T</sub> = (PaCO<sub>2</sub> − P<sub>E</sub>CO<sub>2</sub>) / PaCO<sub>2</sub></div>
<p>P<sub>E</sub>CO<sub>2</sub> is the mean expired partial pressure of CO<sub>2</sub>, measured by metabolic monitor or capnography in mechanically ventilated patients.</p>
<!-- 11. SUMMARY TABLE -->
<h2>11. Summary Comparison Table</h2>
<table>
<thead><tr><th>Feature</th><th>VBG</th><th>ABG</th></tr></thead>
<tbody>
<tr><td>Invasiveness</td><td>Low (venipuncture)</td><td>Higher (arterial puncture)</td></tr>
<tr><td>Pain</td><td>Minimal</td><td>Moderate</td></tr>
<tr><td>pH accuracy</td><td>Good (±0.03–0.05)</td><td>Reference standard</td></tr>
<tr><td>PCO<sub>2</sub></td><td>~3–8 mmHg higher than arterial</td><td>Reference</td></tr>
<tr><td>PO<sub>2</sub> / Oxygenation</td><td>❌ Not useful</td><td>✅ Required for O<sub>2</sub> assessment</td></tr>
<tr><td>HCO<sub>3</sub><sup>−</sup></td><td>~2–3 mEq/L higher</td><td>Reference</td></tr>
<tr><td>Lactate</td><td>Acceptable (screen); confirm if mildly elevated</td><td>More accurate</td></tr>
<tr><td>Use in shock / hypotension</td><td>⚠ Unreliable</td><td>✅ Preferred</td></tr>
<tr><td>Mixed venous O<sub>2</sub> (SvO<sub>2</sub>)</td><td>Via PAC only</td><td>N/A</td></tr>
</tbody>
</table>
<!-- REFERENCES -->
<div class="refs">
<h3>References</h3>
<ul>
<li>Tintinalli's Emergency Medicine: A Comprehensive Study Guide, pp. 304–310</li>
<li>Murray & Nadel's Textbook of Respiratory Medicine, pp. 2270–2282</li>
<li>Goldman-Cecil Medicine International Edition, p. 754</li>
<li>Fishman's Pulmonary Diseases and Disorders, p. 2060</li>
<li>Miller's Anesthesia 10th Edition, pp. 833–835</li>
<li>Rosen's Emergency Medicine: Concepts and Clinical Practice, pp. 2550–2551</li>
<li>Harrison's Principles of Internal Medicine 22E (2025)</li>
</ul>
</div>
<div class="footer">Venous Blood Gases — Orris Medical Reference | June 2026</div>
</body>
</html>
libreoffice --headless --convert-to pdf /home/daytona/workspace/vbg-pdf/vbg.html --outdir /home/daytona/workspace/vbg-pdf/ 2>&1
cp /home/daytona/workspace/vbg-pdf/vbg.html /tmp/vbg.html && libreoffice --headless --convert-to pdf /tmp/vbg.html --outdir /tmp/ 2>&1 && cp /tmp/vbg.pdf /home/daytona/workspace/vbg-pdf/Venous_Blood_Gases.pdf && ls -lh /home/daytona/workspace/vbg-pdf/Venous_Blood_Gases.pdf
Venous Blood Gases
PDF Document · PDF
ECG analysis of this in detail
| Field | Details |
|---|---|
| Name | Shabeer |
| ID | 53336 |
| Age/Sex | 43 years, Male |
| Date/Time | 23-06-2026, 09:13:14 AM |
| Settings | 0.67-35 Hz filter, AC50, 25 mm/s paper speed, 10 mm/mV gain |
| Parameter | Value | Normal Range |
|---|---|---|
| Heart Rate (HR) | 111 bpm | 60-100 bpm |
| PR interval | 134 ms | 120-200 ms |
| QRS duration | 103 ms | <120 ms |
| P axis | 93 ms | -- |
| QRS-T (QTc/QT) | 353/477 ms | QTc <440 ms (men) |
| RVS/SV1 | 0.264/0.621 mV | -- |
Incomplete RBBB is often a normal variant, especially in younger individuals and athletes. However, in a 43-year-old male presenting with tachycardia, causes such as right ventricular pressure overload (pulmonary embolism, pulmonary hypertension), atrial septal defect, or ischaemia should be excluded clinically.
| Category | Examples |
|---|---|
| Electrolyte abnormalities | Hypokalaemia, hypomagnesaemia, hypocalcaemia |
| Medications | Antiarrhythmics (amiodarone, sotalol), antibiotics (azithromycin, fluoroquinolones), antipsychotics, antihistamines |
| Cardiac | Myocarditis, cardiomyopathy, ischaemia |
| Congenital | Long QT syndrome (LQTS type 1, 2, 3) |
| Autonomic | Raised intracranial pressure, hypothyroidism |
| Lead | Key Finding |
|---|---|
| I | Upright P, normal QRS, slurred S wave (RBBB) |
| II | Upright P wave; sinus tachycardia confirmed |
| III | Small complexes, normal |
| aVR | Inverted P and QRS (normal for aVR) |
| aVL | T wave inversion - lateral/high lateral repolarisation abnormality |
| aVF | Normal, positive QRS |
| V1 | rSR' pattern (RBBB), T wave inversion (secondary/expected), large negative P terminal component (left atrial enlargement) |
| V2 | rSR' with T wave inversion (RBBB secondary change) |
| V3 | Transitional zone |
| V4 | Normal transition |
| V5 | Wide S wave (RBBB), upright T |
| V6 | Slurred S wave (RBBB), upright T |
| Finding | Classification | Significance |
|---|---|---|
| Sinus tachycardia (111 bpm) | Abnormal | Requires clinical cause (pain, fever, anxiety, PE, thyrotoxicosis, dehydration, anaemia) |
| Incomplete RBBB (QRS 103 ms) | Abnormal / may be normal variant | Exclude RV pressure overload, ASD, ischaemia |
| T wave inversions (aVL, V1, V2) | V1-V2: secondary to RBBB (expected); aVL: needs correlation | Rule out lateral ischaemia if new |
| Prolonged QTc (477 ms) | Abnormal | Check electrolytes (K+, Mg2+, Ca2+), medications, LQTS; JTc preferred in RBBB |
| Large P terminal force V1 | Suggestive | Left atrial abnormality / enlargement - consider echocardiogram |

⚠️ Disclaimer: This analysis is based on the machine printout and visual tracing. All ECG findings must be clinically correlated by the treating physician. This report does not replace formal cardiologist review.
Immune thrombocytopenic purpura diagnosis treatment pathology etiology
dengue, shigella lepto brusellosis in detail
Liver cirrhosis diagnosis, treatment, pathophysiology, etiology

| Cause | Key Features |
|---|---|
| Alcoholic liver disease (ALD) | Dose and duration dependent; steatohepatitis → fibrosis → cirrhosis |
| Non-alcoholic fatty liver disease (NAFLD) / MASH | Metabolic syndrome; increasingly the most common cause globally |
| Chronic hepatitis B (HBV) | Direct cytopathic + immune-mediated injury; can lead to cirrhosis even without inflammation |
| Chronic hepatitis C (HCV) | Immune-mediated; decades of smouldering fibrosis |
| Nodule Type | Size | Associated Cause |
|---|---|---|
| Micronodular | <3 mm | Alcoholic cirrhosis, haemochromatosis, biliary cirrhosis |
| Macronodular | >3 mm | Viral hepatitis, autoimmune |
| Mixed | Both | Any advanced cirrhosis |
Splanchnic vasodilation → decreased effective arterial blood volume → RAAS + SNS activation → sodium/water retention → expanded plasma volume → hyperdynamic state (↑CO, ↓SVR, ↓MAP)

| Stage | Features | Median Survival |
|---|---|---|
| Compensated | May be asymptomatic; incidental findings | >12 years |
| Decompensated | Ascites, variceal haemorrhage, encephalopathy, jaundice | ~2 years |
| Sign | Cause |
|---|---|
| Spider naevi | Dilated cutaneous arterioles (oestrogen ↑) |
| Palmar erythema | Increased oestrogen |
| Caput medusae | Dilated periumbilical collaterals |
| Leukonychia (white nails) | Hypoalbuminaemia |
| Terry's nails | Cirrhosis-specific white nails |
| Dupuytren's contracture | Alcoholic cirrhosis |
| Parotid enlargement | Alcohol |
| Gynaecomastia / testicular atrophy | Feminisation from ↑ oestrogens |
| Grade | Features |
|---|---|
| 0 (Minimal) | No overt symptoms; neuropsychological testing abnormal |
| 1 | Mild confusion, altered sleep, shortened attention |
| 2 | Lethargy, moderate confusion, asterixis (liver flap) |
| 3 | Stupor, marked confusion, incomprehensible speech |
| 4 | Coma |
| Test | Finding in Cirrhosis |
|---|---|
| ALT/AST | May be normal in advanced cirrhosis (burnt-out liver) |
| ALP/GGT | Elevated (cholestatic component) |
| Bilirubin | Elevated (failure of excretion) |
| Albumin | Decreased (synthetic failure) - useful prognostic marker |
| Prothrombin time / INR | Prolonged (decreased clotting factor synthesis) |
| Platelets | Decreased (hypersplenism + decreased thrombopoietin) |
| Sodium | Hyponatraemia (dilutional) |
| Creatinine | Elevated if HRS developing |
| Ammonia | Elevated in HE (not sensitive/specific alone) |
| AFP | Screen for HCC |
| Modality | Findings in Cirrhosis |
|---|---|
| Ultrasound | Nodular/heterogeneous echogenicity; small liver; splenomegaly; ascites; portal vein dilation; reversed portal flow |
| CT (triple phase) | Nodularity; hypertrophied caudate lobe; splenomegaly; varices; ascites; can detect HCC |
| MRI | Superior soft tissue characterisation; MR elastography for fibrosis staging |
| Upper GI endoscopy | Gold standard for varices; grade and risk-stratify oesophageal varices |
| Component | 1 point | 2 points | 3 points |
|---|---|---|---|
| Bilirubin (mg/dL) | ≤2 | 2-3 | ≥3 |
| INR | ≤1.6 | 1.7-2.2 | ≥2.3 |
| Albumin (g/dL) | ≥3.5 | 2.8-3.5 | ≤2.7 |
| Ascites | None | Slight | Moderate |
| Hepatic encephalopathy | None | Grade 1-2 | Grade 3-4 |
| Class | Score | 1-yr Survival | 2-yr Survival |
|---|---|---|---|
| A (Compensated) | 5-6 | 100% | 85% |
| B (Significant dysfunction) | 7-9 | 80% | 60% |
| C (Decompensated) | 10-15 | 45% | 35% |
MELD = 3.78 × ln[bilirubin mg/dL] + 11.2 × ln[INR] + 9.57 × ln[creatinine mg/dL] + 6.43
| Cause | Disease-Modifying Treatment |
|---|---|
| Alcoholic liver disease | Complete alcohol cessation; nutritional support; prednisolone (severe alcoholic hepatitis) |
| HCV | Direct-acting antivirals (DAAs) - >95% cure rate; fibrosis may regress after SVR |
| HBV | Tenofovir or entecavir (suppress viral replication; slow fibrosis) |
| NAFLD/MASH | Weight loss ≥7-10%; bariatric surgery; GLP-1 agonists; resmetirom (first approved drug for MASH) |
| Haemochromatosis | Phlebotomy (reduce iron); chelation |
| Wilson disease | Penicillamine or trientine (copper chelation); zinc |
| Autoimmune hepatitis | Prednisolone ± azathioprine |
| PBC | Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day; obeticholic acid (2nd line) |
| PSC | UDCA (controversial); endoscopic stricture management; transplant |
| Feature | Compensated | Decompensated |
|---|---|---|
| Definition | No major complications | Ascites, variceal haemorrhage, HE, or jaundice |
| Portal pressure (HVPG) | <12 mmHg or threshold | ≥12 mmHg |
| Median survival | >12 years | ~2 years |
| Mechanism | Fibrosis + early portal HTN | Portal HTN + hyperdynamic state + liver failure |
| Priority | Treat underlying cause | Manage complications + transplant evaluation |
Basics of pharmacology and drug names
| Branch | Definition | Mnemonic |
|---|---|---|
| Pharmacokinetics | What the body does to the drug | PK = body acts on drug |
| Pharmacodynamics | What the drug does to the body | PD = drug acts on body |

| Route | Key Features | Example Drugs |
|---|---|---|
| Oral (PO) | Most common, convenient, economical; subject to first-pass metabolism; food may affect absorption | Acetaminophen, amoxicillin, metformin |
| Sublingual (SL) | Under tongue; bypasses first-pass effect; rapid systemic absorption | Nitroglycerin (GTN) |
| Buccal | Between gum and cheek | Fentanyl buccal tablets |
| Intravenous (IV) | 100% bioavailability; fastest onset; no absorption step | Penicillin G, morphine, vancomycin |
| Intramuscular (IM) | Intermediate absorption; depot formulations possible | Vaccines, depot antipsychotics |
| Subcutaneous (SC) | Slower than IM; sustained release possible | Insulin, heparin, adalimumab |
| Inhalation | Direct delivery to lungs; rapid onset; minimises systemic side effects | Salbutamol, fluticasone |
| Transdermal | Slow systemic absorption; sustained release; rate depends on skin lipid solubility | Fentanyl patch, nicotine patch, GTN patch |
| Rectal | 50% bypasses portal circulation; useful when oral not possible | Diazepam rectal (seizures), some antiemetics |
| Intrathecal | Direct CNS delivery (bypasses blood-brain barrier) | Spinal anaesthesia, intrathecal methotrexate |
| Topical | Local effect at application site | Hydrocortisone cream, eye drops |
Ionised (charged) drugs cannot cross lipid membranes. Non-ionised (uncharged) drugs cross freely.
F = (AUC oral / AUC IV) × 100%
Vd = Dose / Initial plasma concentration (C₀)
| Vd | Where Drug Distributes | Example |
|---|---|---|
| ~4 L (plasma only) | High molecular weight or highly protein-bound; stays in vascular compartment | Heparin, large antibodies |
| ~14 L (extracellular fluid) | Small, hydrophilic; crosses capillaries but not cells | Aminoglycosides |
| ~42 L (total body water) | Small, lipophilic; distributes into all body water | Ethanol |
| >100 L (extensive tissue) | Highly lipophilic; sequesters in fat/tissues | Chloroquine, amiodarone |

| CYP Isoform | % Drug Metabolism | Key Substrates | Key Inhibitors | Key Inducers |
|---|---|---|---|---|
| CYP3A4/5 | 36% (largest) | Statins, benzodiazepines, cyclosporine, midazolam, many others | Ketoconazole, ritonavir, clarithromycin, grapefruit juice | Rifampicin, carbamazepine, St John's Wort |
| CYP2D6 | 19% | Codeine, β-blockers, antidepressants, antipsychotics | Fluoxetine, paroxetine, haloperidol | (not significantly inducible) |
| CYP2C8/9 | 16% | Warfarin, NSAIDs, sulfonylureas | Fluconazole, amiodarone | Rifampicin |
| CYP1A2 | 11% | Caffeine, theophylline, clozapine | Fluvoxamine, ciprofloxacin | Smoking, omeprazole |
| CYP2C19 | 8% | Omeprazole, clopidogrel (prodrug!), diazepam | Omeprazole, fluoxetine | Rifampicin |
| Prodrug | Active Metabolite |
|---|---|
| Codeine | Morphine (via CYP2D6) |
| Clopidogrel | Active thiol metabolite (via CYP2C19) |
| Enalapril | Enalaprilat |
| Levodopa | Dopamine |
| Prednisone | Prednisolone |
| Process | Description |
|---|---|
| Glomerular filtration | Free (unbound) drug filters into Bowman's capsule; protein-bound drug stays in blood; GFR ~120 mL/min |
| Active tubular secretion | Carrier-mediated transport of drugs into tubular lumen; can transport protein-bound drug; may saturate |
| Passive tubular reabsorption | Lipophilic, non-ionised drugs reabsorbed back into blood; ionised drugs remain in urine and are excreted |
t½ = 0.693 × Vd / Cl (where Cl = clearance)
| Receptor Type | Location | Signalling | Examples |
|---|---|---|---|
| Ligand-gated ion channels | Cell membrane | Direct ion flow on binding | Nicotinic ACh receptor, GABA-A, glutamate receptors |
| G-protein coupled receptors (GPCRs) | Cell membrane | Activate G-proteins → second messengers (cAMP, IP3, Ca²⁺) | β-adrenergic, muscarinic, opioid, dopamine receptors |
| Enzyme-linked receptors | Cell membrane | Receptor has intrinsic kinase activity | Insulin receptor, growth factor receptors |
| Intracellular receptors | Cytoplasm/nucleus | Drug must be lipophilic to enter cell; activate gene transcription | Glucocorticoid, thyroid hormone, steroid receptors |
| Term | Definition | Example |
|---|---|---|
| Agonist | Binds receptor AND activates it (produces response) | Morphine (opioid agonist), salbutamol (β₂ agonist) |
| Full agonist | Produces maximum possible response | Morphine |
| Partial agonist | Binds receptor but produces submaximal response; can block full agonists | Buprenorphine |
| Antagonist | Binds receptor but does NOT activate it; blocks agonist binding | Naloxone (opioid antagonist), atropine (muscarinic antagonist) |
| Competitive antagonist | Competes with agonist for same receptor; can be overcome by ↑ agonist dose | Atropine, metoprolol |
| Non-competitive antagonist | Binds irreversibly or allosteric site; cannot be overcome by ↑ agonist dose | Phenoxybenzamine |
| Inverse agonist | Binds receptor and produces opposite effect to agonist | Some antihistamines |
| Parameter | Definition | Clinical relevance |
|---|---|---|
| Potency (ED50) | Dose producing 50% maximum effect | Compares relative drug strength; does NOT imply safety or efficacy |
| Efficacy (Emax) | Maximum effect achievable regardless of dose | Partial agonists have lower efficacy than full agonists |
| EC50 | Concentration producing 50% maximum effect | Lower EC50 = more potent |
TI = TD50 / ED50 (or LD50 / ED50 in animal studies)
| Name Type | Definition | Example |
|---|---|---|
| Chemical name | Precise chemical structure (IUPAC) | N-acetyl-para-aminophenol |
| Generic name (INN) | International Non-proprietary Name; standardised name | Paracetamol (UK) / Acetaminophen (USA) |
| Brand/Trade name | Manufacturer's proprietary name (capitalised) | Panadol®, Tylenol® |
| Stem | Drug Class | Examples |
|---|---|---|
| -olol | β-blockers (beta-adrenergic antagonists) | Propranolol, metoprolol, atenolol, carvedilol |
| -dipine | Calcium channel blockers (dihydropyridines) | Amlodipine, nifedipine, felodipine |
| -pril | ACE inhibitors | Enalapril, lisinopril, ramipril, captopril |
| -sartan | Angiotensin II receptor blockers (ARBs) | Losartan, valsartan, irbesartan, candesartan |
| -statin | HMG-CoA reductase inhibitors (statins) | Atorvastatin, rosuvastatin, simvastatin |
| -fibrate | Fibrates (lipid-lowering) | Fenofibrate, gemfibrozil |
| -tidine | H₂ receptor antagonists | Ranitidine, famotidine, cimetidine |
| -floxacin | Fluoroquinolone antibiotics | Ciprofloxacin, levofloxacin, moxifloxacin |
| Stem | Drug Class | Examples |
|---|---|---|
| -cillin | Penicillins | Amoxicillin, ampicillin, piperacillin, flucloxacillin |
| -cycline | Tetracyclines | Doxycycline, tetracycline, minocycline |
| -mycin / -micin | Aminoglycosides or macrolides | Gentamicin, tobramycin (amino); Erythromycin, azithromycin, clarithromycin (macrolide) |
| -azole | Antifungals (azoles) or antiprotozoals | Fluconazole, ketoconazole, metronidazole |
| -navir | HIV protease inhibitors | Ritonavir, lopinavir, atazanavir, darunavir |
| -vir | Antivirals | Aciclovir, oseltamivir, sofosbuvir, tenofovir |
| -ovir | Antivirals (herpes/HIV) | Aciclovir, ganciclovir, entecavir |
| -conazole | Antifungals | Fluconazole, itraconazole, voriconazole |
| Stem | Drug Class | Examples |
|---|---|---|
| -pam / -lam | Benzodiazepines | Diazepam, lorazepam, midazolam, alprazolam |
| -pine | Tricyclic antidepressants or antipsychotics | Amitriptyline, clomipramine, clozapine, olanzapine |
| -triptan | Serotonin (5-HT1B/1D) agonists (migraine) | Sumatriptan, rizatriptan, zolmitriptan |
| -prazole | Proton pump inhibitors | Omeprazole, lansoprazole, pantoprazole, esomeprazole |
| -tidine | H₂ blockers | Ranitidine, famotidine |
| cef- / ceph- | Cephalosporins | Cefuroxime, ceftriaxone, cefalexin |
| Stem | Drug Class | Examples |
|---|---|---|
| -glitazone | PPAR-γ agonists (thiazolidinediones) | Pioglitazone, rosiglitazone |
| -formin | Biguanides | Metformin |
| -gliptin | DPP-4 inhibitors | Sitagliptin, saxagliptin, vildagliptin |
| -gliflozin | SGLT-2 inhibitors | Empagliflozin, dapagliflozin, canagliflozin |
| -glutide | GLP-1 receptor agonists | Semaglutide, liraglutide, exenatide |
| -glimide | Sulfonylureas | Glipizide, glibenclamide, gliclazide |
[prefix] - [target] - [source] - mab
| Component | Meaning | Examples |
|---|---|---|
| -mab | Monoclonal antibody | Indicates entire class |
| -u- | Human origin | Adalimumab, ustekinumab |
| -xi- | Chimeric (part mouse, part human) | Infliximab, rituximab |
| -zu- | Humanised | Trastuzumab, bevacizumab |
| -o- | Mouse origin (mostly obsolete) | Muronomab |
| Drug | Target | Use |
|---|---|---|
| Adalimumab (Humira) | TNF-α | Rheumatoid arthritis, IBD, psoriasis |
| Infliximab (Remicade) | TNF-α | IBD, rheumatoid arthritis |
| Trastuzumab (Herceptin) | HER2 | HER2+ breast/gastric cancer |
| Rituximab (MabThera) | CD20 | B-cell lymphomas, RA |
| Bevacizumab (Avastin) | VEGF | Colorectal, lung, ovarian cancers |
| Pembrolizumab (Keytruda) | PD-1 | Multiple cancers (checkpoint inhibitor) |
| Nivolumab (Opdivo) | PD-1 | Multiple cancers |
| Omalizumab (Xolair) | IgE | Allergic asthma |
| Denosumab (Prolia) | RANK-L | Osteoporosis, bone metastases |
| Mechanism | Effect | Example |
|---|---|---|
| CYP3A4 inhibition | ↑ drug levels → toxicity | Ketoconazole + simvastatin → rhabdomyolysis |
| CYP induction | ↓ drug levels → failure | Rifampicin + oral contraceptive pill → pregnancy |
| P-gp inhibition | ↑ drug absorption | Clarithromycin + digoxin → digoxin toxicity |
| Protein binding displacement | ↑ free drug | Aspirin + warfarin → bleeding |
| Renal competition | ↑ drug retention | Probenecid + penicillin → ↑ penicillin levels (used therapeutically) |
| Type | Example |
|---|---|
| Synergism | Two drugs with same effect given together (additive or supra-additive) - e.g. alcohol + benzodiazepines → CNS depression |
| Antagonism | One drug blocks effect of another - e.g. naloxone reverses morphine |
| Potentiation | One drug increases effect of another without having same action alone |
| Concept | Key Point |
|---|---|
| ADME | Absorption, Distribution, Metabolism, Elimination |
| Bioavailability | IV = 100%; oral reduced by first-pass |
| Vd | Small = stays in plasma; Large = distributes into tissues |
| t½ | 5 half-lives to steady state or washout |
| CYP3A4 | Metabolises 36% of all drugs; major interaction site |
| Prodrugs | Codeine, clopidogrel, enalapril - activated by metabolism |
| Narrow TI | Warfarin, digoxin, lithium, phenytoin - need therapeutic drug monitoring |
| Agonist | Activates receptor |
| Antagonist | Blocks receptor |
| Potency vs. efficacy | Potency = dose needed; Efficacy = maximum effect achievable |
| INN stems | -olol = β-blocker; -pril = ACEi; -sartan = ARB; -statin = statin; -mab = monoclonal antibody |
Diuretics

| Class | Site of Action | Transporter Blocked | Na⁺ Excretion | K⁺ Effect | Key Drug |
|---|---|---|---|---|---|
| Osmotic | Proximal tubule + descending loop | None (osmotic) | Moderate | Neutral | Mannitol |
| Carbonic anhydrase inhibitors | Proximal tubule (Site I) | H⁺/HCO₃⁻ (CA enzyme) | Weak | ↓K⁺ (lose K⁺) | Acetazolamide |
| Loop diuretics | Thick ascending limb (Site II) | NKCC2 (Na⁺-K⁺-2Cl⁻) | Strongest: 20-25% | ↓K⁺ (hypokalaemia) | Furosemide |
| Thiazides | Distal convoluted tubule (Site III) | NCC (Na⁺-Cl⁻) | Moderate: 5-10% | ↓K⁺ (hypokalaemia) | Hydrochlorothiazide |
| K⁺-sparing (MRAs) | Collecting duct (Site IV) | Mineralocorticoid receptor | Weak | ↑K⁺ (spare K⁺) | Spironolactone |
| K⁺-sparing (ENaC blockers) | Collecting duct (Site IV) | ENaC (Na⁺ channel) | Weak | ↑K⁺ (spare K⁺) | Amiloride, Triamterene |
| SGLT2 inhibitors | Proximal tubule S1/S2 (Site I) | SGLT2 (Na⁺-glucose) | Mild | Neutral | Empagliflozin |
| Drug | Initial Dose | Max Daily Dose | Duration of Action | Notes |
|---|---|---|---|---|
| Furosemide | 20-40 mg OD/BD | 600 mg | 6-8 hours | Most commonly used; IV for acute pulmonary oedema |
| Bumetanide | 0.5-1 mg OD/BD | 10 mg | 4-6 hours | 40x more potent than furosemide mg-for-mg |
| Torsemide | 10-20 mg OD | 200 mg | 12-16 hours | Better oral bioavailability than furosemide (~80% vs ~50%) |
| Ethacrynic acid | 25-50 mg OD/BD | 200 mg | 6 hours | Only loop diuretic NOT sulfonamide-based; use in sulfa allergy |
| Side Effect | Mechanism |
|---|---|
| Hypokalaemia | ↑ Na⁺ delivery to collecting duct → ↑ K⁺ secretion; ↑ aldosterone |
| Hyponatraemia | Excessive free water loss |
| Hypomagnesaemia | Loss in urine (same paracellular mechanism as Ca²⁺) |
| Hypocalcaemia | Hypercalciuria → chronic depletion |
| Metabolic alkalosis | K⁺ loss → H⁺ shifts into cells; contraction alkalosis |
| Ototoxicity | Toxic to cochlear hair cells; dose-dependent; reversible (usually); worse with aminoglycosides |
| Hyperuricaemia | Compete with uric acid for OAT secretion → reduced urate excretion → gout |
| Hypovolaemia / prerenal AKI | Excessive diuresis |
| Hyperglycaemia | (mild, less than thiazides) |
| Sulfonamide allergy | Furosemide, bumetanide, torsemide contain sulfonamide group → use ethacrynic acid if severe sulfa allergy |
| Drug | Notes |
|---|---|
| Hydrochlorothiazide (HCTZ) | Most widely used thiazide |
| Chlorthalidone | Longer-acting; preferred in guidelines for hypertension; more potent CV benefit |
| Indapamide | Thiazide-like; also has direct vasodilatory effect |
| Metolazone | Thiazide-like; also acts on proximal tubule; used in combination with furosemide for diuretic resistance in heart failure; effective even in CKD |
| Bendroflumethiazide | Commonly used in UK for hypertension |
| Side Effect | Mechanism / Notes |
|---|---|
| Hypokalaemia | ↑ Na⁺ delivery to collecting duct → K⁺ secretion; most common |
| Hyponatraemia | Impairs free water clearance; most dangerous electrolyte effect |
| Hyperglycaemia | ↓ Insulin secretion (K⁺ depletion reduces beta-cell function) |
| Dyslipidaemia | ↑ LDL, triglycerides (dose-dependent) |
| Hyperuricaemia / gout | Compete with uric acid excretion |
| Hypomagnesaemia | Direct Mg²⁺ wasting in DCT |
| Hypercalcaemia | ↑ Ca²⁺ reabsorption → raise serum Ca²⁺ |
| Metabolic alkalosis | K⁺ loss + contraction alkalosis |
| Photosensitivity | Sulfonamide derivative → rash |
| Sexual dysfunction | Less common with newer agents |
"GLUC" goes UP: Glucose, Lipids, Uric acid, Calcium "SNAP" goes DOWN: Sodium, Na (filtered), K (potassium), Mg (magnesium)
| Drug | Generation | Notes |
|---|---|---|
| Spironolactone | 1st (steroidal) | Structural analogue of aldosterone; anti-androgenic side effects |
| Eplerenone | 2nd (steroidal) | More selective; fewer sex hormone side effects than spironolactone |
| Finerenone | 3rd (non-steroidal) | Most selective; less hyperkalaemia; approved for CKD + T2DM |
| Drug | Use | Notes |
|---|---|---|
| Amiloride | Combined with HCTZ (e.g. Co-amilozide); treatment-resistant hypertension | Pure K⁺-sparing effect |
| Triamterene | Combined with HCTZ (Dyazide®, Maxzide®) | Can crystallise in urine → nephrolithiasis |
| Drug | Key Trial | Key Indication |
|---|---|---|
| Empagliflozin (Jardiance) | EMPA-REG OUTCOME | T2DM, HFrEF, CKD |
| Dapagliflozin (Forxiga) | DAPA-HF, DECLARE-TIMI | T2DM, HFrEF, HFpEF, CKD |
| Canagliflozin (Invokana) | CANVAS, CREDENCE | T2DM, CKD |
| Cause | Solution |
|---|---|
| Reduced oral bioavailability | Switch to IV route |
| Hypoalbuminaemia → less drug delivered to tubule | Albumin infusion before furosemide |
| Reduced GFR → less drug secreted | Increase dose |
| RAAS activation by loop diuretic | Add MRA (spironolactone) |
| Distal tubule hypertrophy (adaptation) | Add thiazide (especially metolazone) |
| Poor Na⁺ restriction | Sodium restriction + dietary counselling |
| High albumin binding | Use bolus then continuous IV infusion |
| Feature | Loop | Thiazide | K⁺-sparing (MRA) | CA Inhibitor | Osmotic |
|---|---|---|---|---|---|
| Potency | Highest (20-25%) | Moderate (5-10%) | Weak (2-3%) | Weak | Moderate |
| K⁺ effect | ↓ (lose K⁺) | ↓ (lose K⁺) | ↑ (spare K⁺) | ↓ (lose K⁺) | Neutral |
| Ca²⁺ effect | ↑ excretion (hypercalciuria) | ↓ excretion (hypocalciuria) | Neutral | ↑ excretion | Neutral |
| Acid-base | Metabolic alkalosis | Metabolic alkalosis | Metabolic acidosis | Metabolic acidosis | Neutral |
| Works in CKD? | Yes | No (Clcr <40) | Use caution | Yes | Yes |
| Key interaction | Ototoxicity + aminoglycosides | ↑ digoxin toxicity (via hypokalaemia) | Hyperkalaemia + ACEi/K⁺ supplements | Sulfa allergy | Pulmonary oedema |
parathyroid gland and its disorders in detail trousseau sign calcium levels